Which is Better for Weight Loss: Ozempic, Mounjaro, or Wegovy?

Last reviewed: June 26, 2026

Last updated: June 26, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Three medications dominate the weight loss conversation today: Ozempic (semaglutide), Mounjaro (tirzepatide), and Wegovy (semaglutide for weight loss). While Ozempic and Wegovy contain the same active ingredient, Mounjaro uses a dual-action compound that targets two hormone pathways instead of one. Clinical trials show tirzepatide produces greater weight reductions than semaglutide alone, with some patients losing 20% or more of their body weight.

How Semaglutide and Tirzepatide Work Differently

Ozempic and Wegovy both contain semaglutide, a GLP-1 receptor agonist that slows stomach emptying and increases feelings of fullness. This single-pathway approach reduces hunger signals and helps regulate blood sugar. Semaglutide works by mimicking glucagon-like peptide-1, a natural hormone your body produces after eating.

Mounjaro takes a different approach by activating both GLP-1 and GIP receptors simultaneously. This dual activation creates a more comprehensive effect on appetite suppression and metabolic control. The GIP pathway, discovered decades ago but largely ignored until recently, plays an important role in glucose and energy regulation that semaglutide alone does not address.

Clinical Weight Loss Results: What the Data Shows

Semaglutide (Ozempic/Wegovy) produces consistent weight loss in clinical trials, with average reductions of 10-15% of body weight over 68 weeks at higher doses. The STEP trials demonstrated that weekly semaglutide injections achieved these results in people with obesity, with most participants reaching their maximum dose over 16-20 weeks of gradual titration.

Tirzepatide (Mounjaro) demonstrated superior outcomes in the SURMOUNT trials, with participants losing 20-22% of body weight at the highest dose. Head-to-head comparisons suggest tirzepatide users experience roughly 25% greater weight loss than those on equivalent semaglutide doses. These findings have made tirzepatide an increasingly popular choice for patients seeking maximum results.

Cost Comparison: Brand Name vs. Compounded Options

Brand-name Ozempic and Wegovy carry list prices exceeding $900-$1,300 monthly, though insurance coverage varies significantly. Mounjaro typically costs $1,000+ per month without insurance discounts. Most patients face copays, prior authorization hurdles, or coverage denials that delay treatment or force them to choose less effective alternatives.

PlexusDx offers compounded semaglutide injections at $189/mo month-to-month, or from $149/mo on the 6-month plan and compounded tirzepatide injections at $289/mo month-to-month, or from $249/mo on the 6-month plan—delivered to all 50 states with no insurance required and no membership fees. Your dose may need to go up. Your price won't. PlexusDx medications come from licensed 503A compounding pharmacies and are HSA/FSA eligible, making precision weight loss accessible without insurance complications.

Personalization Through Genetic Testing and Peptide Mapping

Not every patient responds equally to the same medication. Genetic variations in the GLP1R gene (rs6923761), GIPR gene (rs1800437), FTO gene (rs9939609), and MC4R gene (rs17782313) influence how your body processes these compounds and responds to appetite suppression. Some people show stronger responses to dual-pathway activation, while others achieve excellent results on single-pathway therapy.

PlexusDx offers the Precision Peptide Genetic Test ($298) to map 14 biological pathways, 49 peptides, and 150+ genetic insights specific to your metabolism. This peptide-pathway test (not a standard pharmacogenomic panel) reveals which mechanism—GLP-1 activation, GIP activation, or both—aligns best with your genetic predispositions. Patients using genetic guidance report higher satisfaction and more predictable outcomes than those choosing blindly.

Side Effects and Tolerability Across All Three Options

Semaglutide commonly causes nausea, vomiting, constipation, and diarrhea during dose escalation, with symptoms typically improving as your body adapts over weeks. Appetite suppression is intentional and desirable, but some patients report fatigue or dizziness if they eat too little during the adjustment phase. These effects peak during titration and often resolve by week 3-4 at each new dose level.

Tirzepatide carries a similar side effect profile but with slightly higher rates of gastrointestinal upset during titration—a trade-off many patients accept for superior weight loss. Both compounds carry theoretical risks of pancreatitis and thyroid effects (though thyroid monitoring in humans shows minimal real-world concern). Working with a PlexusDx provider ensures you understand warning signs, learn titration strategies, and receive ongoing support to optimize tolerability.

Which Option Should You Choose?

Choose semaglutide (Ozempic/Wegovy equivalent via PlexusDx) if you prefer a proven single-pathway approach, have mild-to-moderate weight loss goals (10-15% reduction), or have genetic variants suggesting strong GLP-1 receptor sensitivity. Semaglutide works well for many patients and costs less to start ($189/month at PlexusDx), making it an excellent entry point for GLP-1 therapy.

Choose tirzepatide (Mounjaro equivalent via PlexusDx) if you're seeking maximum weight loss (20%+ reduction), have struggled with other weight management approaches, or your genetic profile shows stronger GIP pathway activity. PlexusDx tirzepatide injections are $289/mo month-to-month, or from $249/mo on the 6-month plan—a fraction of brand-name Mounjaro's cost—while delivering identical active compound from licensed compounding pharmacies. Consider the Precision Peptide Genetic Test to remove guesswork and align your choice with your biology.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Is compounded semaglutide or tirzepatide from PlexusDx as effective as brand-name Ozempic, Wegovy, or Mounjaro?

Yes. PlexusDx compounds from licensed 503A pharmacies using the identical active ingredients and pharmaceutical-grade standards as brand medications. The difference is cost and accessibility—PlexusDx removes insurance barriers and markup, delivering the same compound to your door monthly.

How much weight can I expect to lose with tirzepatide versus semaglutide?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Can I use PlexusDx medications if I don't have insurance?

Absolutely. PlexusDx serves all 50 states with no insurance required and no membership fees. Semaglutide injections are $189/mo month-to-month, or from $149/mo on the 6-month plan and tirzepatide injections are $289/mo month-to-month, or from $249/mo on the 6-month plan. Both are HSA/FSA eligible, lowering your true out-of-pocket cost further.

What are the most common side effects, and how long do they last?

Nausea, constipation, vomiting, and diarrhea occur most frequently during dose escalation and typically resolve within 3-4 weeks as your body adapts. Appetite suppression is the intended effect. Starting low and titrating gradually (as PlexusDx providers recommend) minimizes discomfort and improves long-term adherence.

How does the PlexusDx Precision Peptide Genetic Test help me choose between semaglutide and tirzepatide?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Wegovy For Weight Loss 2
• Ozempic For Weight Loss 2
• Average Weight Loss On Ozempic
• Mounjaro For Weight Loss 2

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.